Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis Subjects (MEASURE)

This study has been completed.
Sponsor:
Collaborator:
EMD Inc., Canada
Information provided by (Responsible Party):
Merck KGaA
ClinicalTrials.gov Identifier:
NCT01128075
First received: May 20, 2010
Last updated: July 8, 2014
Last verified: July 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2014
  Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)